Skip to main content

Market Overview

UPDATE: Benchmark Initiates Coverage on Abiomed on Potential of Impella Device

Share:

In a report published Tuesday, Benchmark Company analyst Jan Wald initiated coverage on Abiomed (NASDAQ: ABMD) with a Speculative Buy rating and $25.00 price target.

In the report, Benchmark Company noted, “We are initiating coverage of Abiomed with a Speculative Buy rating and Price Target of $25. We believe that the company's Impella device offers a compelling benefit to outcomes for patients who need temporary circulatory support, and while the company is facing headwinds from a Department of Justice investigation, we expect that the outcome will be manageable. We also believe the reimbursement decision for the Impella device will be manageable. Abiomed is also participating in the FDA's 515 program to migrate Impella from Class II to Class III which introduces risks but also raises the barrier to entry for competitors. The Impella reduces loading on the heart, compared to the current standard of intra-aortic balloon pumps. Our Speculative Buy rating is supported by our price target of $25, which we derive from a blend of our DCF target price of $29 and our EV/Sales target of $22.”

Abiomed closed on Monday at $19.06.

Latest Ratings for ABMD

DateFirmActionFromTo
Feb 2022Morgan StanleyMaintainsUnderweight
Feb 2022SVB LeerinkMaintainsMarket Perform
Jan 2022Morgan StanleyMaintainsUnderweight

View More Analyst Ratings for ABMD

View the Latest Analyst Ratings

 

Related Articles (ABMD)

View Comments and Join the Discussion!

Posted-In: Benchmark Company Jan WaldAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com